Impact of Intraprostatic Simultaneous Integrated Boost on Long-Term Outcomes in Unfavorable Intermediate-Risk Prostate Cancer Treated With Dose-Escalated Radiotherapy and Short-Term Androgen Deprivation Therapy

Gastrointestinal Cancer

Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles impacting systemic therapy outcomes

Eur J Cancer

Graus MUJE, van Diepen AE, Broekman T, van Eijck CWF, van Hooft JE, Homs MYV, Wumkes ML, Wilmink JW, de Hingh IHJT, Valkenburg-van Iersel LBJ, van der Geest LGM, Vos-Geelen J, Dutch Pancreatic Cancer Group (DPCG)

doi: 10.1016/j.ejca.2026.116263

Genitourinary Cancer

Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis

Prostate Cancer Prostatic Dis

Saporita I, Calabrese M, Carfi FM, Mogavero A, Puglisi M, Treglia G, Vogl UM, Gillessen S, Pereira Mestre R, Pedrani M, Pecoraro G, Salfi G, Erhart CC, Lin HM, Tortola L, Di Maio M, Tucci M, Buttigliero C, Turco F

doi: 10.1038/s41391-026-01077-9

Genitourinary Cancer

Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: Long-term Data from the SAKK 09/10 Randomised Phase 3 Trial

Eur Urol

Ghadjar P, Hayoz S, Zwahlen DR, Hölscher T, Arnold W, Polat B, Hildebrandt G, Hoffmann E, Plasswilm L, Papachristofilou A, Schär C, Sumila M, Zaugg K, Guckenberger M, Ost P, Reuter C, Bosetti DG, Khanfir K, Riesterer O, Beck M, Thalmann GN, Aebersold DM, Swiss Group for Clinical Cancer Research (SAKK)

doi: 10.1016/j.eururo.2025.12.020

Genitourinary Cancer

Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: A Meta-Analysis

JAMA Oncol

Zaorsky NG, Sun Y, Nabid A, Zapatero A, Bolla M, Joseph D, Maingon P, Guerrero A, Gonzalez AA, San-Segundo CG, Cabeza Rodríguez MÁ, Sole JM, Olivé AP, Steigler A, Souhami L, Carrier N, Armstrong JG, Gillham C, Pisansky TM, Schipper M, Sandler HM, Efstathiou JA, Lawton C, de Reijke TM, Attard G, Roy S, Morgan SC, Malone S, Hall WA, Nguyen PL, Shoag JE, Vince RA Jr, Calaway A, Garcia JA, Barata PC, Mendiratta P, Brown JR, Valle L, Rettig M, Dess RT, Jackson WC, Martin T, Jia AY, Steinberg M, Romero T, Kishan AU, Spratt DE

doi: 10.1001/jamaoncol.2025.4800

Genitourinary Cancer

Long-term outcomes of cribriform-positive and cribriform-negative prostate cancer treated with radical prostatectomy in the ProtecT trial

BJU Int

Sushentsev N, Warren AY, Colling R, Verrill C, Pazukhina E, Blyuss O, Zaikin A, Seibert TM, Barrett T, Oxley J, Mills IG, Bryant RJ, Lane JA, Donovan JL, Neal DE, Hamdy FC

doi: 10.1111/bju.70261

Genitourinary Cancer

Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: 10-Year Outcomes of the FLAME Trial

J Clin Oncol

Menne Guricová K, Draulans C, Pos FJ, Kerkmeijer LGW, Monninkhof EM, Smeenk RJ, Kunze-Busch M, de Boer HCJ, van der Voort van der Zyp JRN, Haustermans K, van der Heide UA

doi: 10.1200/JCO-25-00274

Genitourinary Cancer

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol

Lancet Oncol

Gillessen S, Murphy L, James ND, Sachdeva A, El-Taji O, Abdel-Aty H, Adler AI, Amos C, Attard G, Varughese M, Gale J, Brown S, Srihari N, Birtle AJ, Brown M, Chan K, Chowdhury S, Cross W, Dearnaley DP, Din O, Dutey-Magni P, Gilbert DC, Gilson C, Gray S, Grist E, Hofmann U, Hudson AM, Jain Y, Jeyasangar G, Jones R, Kayani M, Langley RE, Malik Z, Mason MD, Matheson D, McAlpine C, Macnair A, Millman R, Murphy C, Padden-Modi M, Parikh O, Parker C, Rush H, Russell M, Srinivasan R, Sundar S, Tanguay JS, Turco F, Williams P, Sydes MR, Parmar MKB, Brown LC, Clarke NW, STAMPEDE investigators

doi: 10.1016/S1470-2045(25)00231-1

Breast Cancer

Impact of whole breast irradiation, endocrine therapy or their combination on outcomes of early-stage, luminal A-like, low-risk, breast cancer patients aged 65 years or over: Insights from the EUSOMA database

Eur J Cancer

Aristei C, Tomatis M, Ponti A, Marotti L, Battisti NML, Leung Cheung K, Hartmann OJ, Rubio IT, Santini D, Sardanelli F, Senkus E, van Dam P, Curigliano G, Eusoma Working Group

doi: 10.1016/j.ejca.2026.116259

Genitourinary Cancer

Long-term outcomes of a cascading salvage strategy for high-risk non-muscle-invasive bladder cancer

BJU Int

McElree IM, Steinberg RL, Hougen HY, Mott SL, Packiam VT, O'Donnell MA

doi: 10.1111/bju.70044

Related content

Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles impacting systemic therapy outcomes

Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis

Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: Long-term Data from the SAKK 09/10 Randomised Phase 3 Trial

Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: A Meta-Analysis

Long-term outcomes of cribriform-positive and cribriform-negative prostate cancer treated with radical prostatectomy in the ProtecT trial

Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: 10-Year Outcomes of the FLAME Trial

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol

Impact of whole breast irradiation, endocrine therapy or their combination on outcomes of early-stage, luminal A-like, low-risk, breast cancer patients aged 65 years or over: Insights from the EUSOMA database

Long-term outcomes of a cascading salvage strategy for high-risk non-muscle-invasive bladder cancer